NASDAQ: IMNMImmunome Inc Stock Ownership - Who owns Immunome?
Insider buying vs selling
Have Immunome Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jack Higgins | Chief Scientific Officer | 2025-09-10 | 22,000 | $1.35 | $29.70kBuy |
| Jean Jacques Bienaime | Director | 2025-06-03 | 5,000 | $9.38 | $46.90kBuy |
| Jack Higgins | Chief Scientific Officer | 2025-03-27 | 5,200 | $1.35 | $7.02kBuy |
| Clay B. Siegall | President and CEO | 2025-03-26 | 137,100 | $7.29 | $999.46kBuy |
| Jean Jacques Bienaime | Director | 2025-03-25 | 7,800 | $7.78 | $60.68kBuy |
| Philip Tsai | Chief Technology Officer | 2025-03-24 | 12,300 | $8.42 | $103.57kBuy |
| Jean Jacques Bienaime | Director | 2025-03-24 | 7,000 | $8.21 | $57.47kBuy |
| Clay B. Siegall | President and CEO | 2025-01-31 | 150,000 | $7.75 | $1.16MBuy |
IMNM insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when IMNM insiders and whales buy or sell their stock.
IMNM Shareholders
What type of owners hold Immunome Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Fmr LLC | 14.24% | 13,056,709 | $243.25M | Institution |
| T Rowe Price Investment Management Inc | 9.18% | 8,418,163 | $156.83M | Institution |
| Blackrock Inc | 6.35% | 5,822,736 | $108.48M | Institution |
| Redmile Group LLC | 5.48% | 5,023,385 | $93.59M | Institution |
| Vanguard Group Inc | 5.34% | 4,893,626 | $91.17M | Institution |
| Point72 Asset Management LP | 5.26% | 4,824,504 | $89.88M | Institution |
| Enavate Sciences GP LLC | 5.20% | 4,768,583 | $88.84M | Institution |
| Ecor1 Capital LLC | 4.45% | 4,079,415 | $76.00M | Institution |
| Price T Rowe Associates Inc | 4.08% | 3,742,770 | $69.73M | Institution |
| Opaleye Management Inc | 3.47% | 3,185,000 | $59.34M | Institution |
IMNM vs Biotech Stocks
Immunome Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.